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SUMMARY
Protein translation is a key process on cell deve-
lopment and proliferation that is often deregulated 
in cancer. MAP kinase interacting kinases 1 and 2 
(Mnk1/2) play a pivotal role in regulating the cap-
dependent translation through phosphorylation of 
eIF4E transcription factor. Thus, Mnk1/2 targeting 
have been proposed as a novel therapeutic strategy 
that would minimize side-effects in contrast to other 
therapies. For this reason, there is a growing interest 
in designing in silico new Mnk1/2 inhibitors which 
demands from reliable structural models. Interestin-
gly, the catalytic domain of Mnk proteins are charac-
terized by a DFD motif instead of the characteristic 
DFG motif of other kinases. However, Mnk2 struc-
tural models described in literature are DFG muta-
ted and do not contain the activation loop. Molecu-
lar design techniques have been applied to obtain a 
structural model of the full wildtype Mnk2 protein 
including the activation loop. The effect of the loop 
on the interaction mechanism of well-known ligands 
has been evaluated. Obtained results suggest that the 
presence of the activation loop is determinant for the 
correct prediction of the active site and it is essential 
for the design of new inhibitors.
Keywords: Drug design; MNK2 inhibition; molec-
ular docking.
RESUMEN
La traducción de proteínas es un proceso clave para 
el desarrollo y la proliferación celular que se encuentra 
desregulado en muchos cánceres. Las proteínas MAP 
kinase interacting kinases 1 and 2 (Mnk1/2) juegan un 
papel fundamental en la traducción cap-dependiente 
regulando la fosforilación del factor eIF4E y se han 
postulado como una diana terapéutica de gran interés 
para intentar minimizar los efectos secundarios de las 
terapias convencionales. Por este motivo, hay un inte-
rés creciente en el diseño in silico de nuevos inhibidores 
de Mnk1/2 que, en consecuencia, requiere de modelos 
estructurales fiables. El dominio catalítico de las pro-
teínas Mnk presenta un motivo DFD que sustituye el 
motivo DFG característico de las proteínas quinasas. 
Sin embargo, en el caso particular de la Mnk2, los mo-
delos estructurales disponibles en la bibliografía pre-
sentan la mutación DFG y les falta el loop de activación. 
Mediante técnicas de diseño molecular se ha obtenido 
un modelo completo de la proteína Mnk2 wildtype que 
incluye el loop de activación y se ha evaluado el efecto 
de éste sobre el mecanismo de interacción de ligandos 
conocidos. Los resultados obtenidos indican que la pre-
sencia del loop de activación es determinante para la 
correcta identificación del centro activo y se considera 
esencial para el diseño de nuevos inhibidores.
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RESUM 
La traducció de proteïnes és un procés clau per al 
desenvolupament i la proliferació cel·lular que es tro-
ba desregulat en molts càncers. Les proteïnes MAP 
kinase interacting kinases 1 and 2 (Mnk1/2) juguen 
un paper fonamental en la traducció cap-depenent 
mediant la fosforilació del factor eIF4E i han esdevin-
gut una diana terapèutica de gran interès per intentar 
minimitzar els efectes secundaris de teràpies conven-
cionals. Per aquest motiu, hi ha un interès creixent en 
el disseny in silico de nous inhibidors de Mnk1/2 que, 
en conseqüència, requereix de models estructurals 
fiables. El domini catalític de les proteïnes Mnk pre-
senta un motiu DFD que substitueix el característic 
motiu DFG de les proteïnes cinases. No obstant, en 
el cas particular de la Mnk2, els models estructurals 
disponibles en la bibliografia presenten la mutació 
DFG i els manca el loop d’activació. Mitjançant tèc-
niques de disseny molecular s’ha obtingut un model 
complet de la proteïna Mnk2 wildtype que inclou el 
loop d’activació i s’ha avaluat l’efecte d’aquest sobre 
el mecanisme d’interacció de lligands coneguts. Els 
resultats obtinguts indiquen que la presència del loop 
d’activació és determinant per a la correcta identifica-
ció del centre actiu i es considera essencial pel disseny 
de nous inhibidors.
Paraules clau: Disseny de fàrmacs; inhibició de 
MNK2; docking molecular.
INTRODUCTION
Overexpression of the components of the translation 
initiation machinery has been correlated to malignant 
transformation. The limiting eukaryotic translation 
initiation factor 4E (eIF4E) was found to be up-regu-
lated in most human cancers1 and has been related to 
poor prognosis2. Overexpression of eIF4E increases the 
translation of mRNAs with a structured 5’ untransla-
ted region (5’ UTR) which are usually translated with 
low efficiency as they include transcription factors, 
growth factors, receptors and tyrosine kinases2-6. 
The mitogen-activated protein kinase (MAPK) inte-
racting protein kinases (Mnks 1/2) are serine/threoni-
ne kinases that regulate the activity of proteins involved 
in diverse cellular functions through phosphorylation. 
Mnk inhibition decreases the levels of phosphorylated 
eIF4E and attenuates the expression of mRNA invol-
ved in cell proliferation becoming a potential strategy 
for the treatment of many cancers. Interestingly, expe-
rimental studies on Mnk1/2 knockout mice conclude 
that eIF4E phosphorylation is crucial for tumorigenesis 
but dispensable for normal cell development7. 
Design of new inhibitors to target Mnk proteins has 
become an interesting starting point for search of no-
vel cancer therapies. In this regard, molecular modelling 
techniques have risen as an effective strategy to guide 
the drug design process. Unfortunately, limited data is 
available on known inhibitors commonly used as refe-
rence for drug design (Figure 1). Moreover, these mo-
lecules are planar heterocyclic systems that mimic the 
adenine moiety of ATP in order to act as ATP competi-
tors and, therefore, present a low specificity for Mnks. In 
view of the lack of ligand-based information, structural 
information about the receptor becomes mandatory to 
allow the application of structure-based drug design.
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Figure 1. Molecular structure of known Mnk1/2 inhibitors 
taken as reference in this study.
Molecular structure of Mnk proteins has a strong 
resemblance to other protein kinases; they have a 
bilobed arrangement in which the N-terminal lobe 
contains the regulatory α-helix (αC), a twisted sheet 
of five antiparallel β-strands and a highly flexible 
glycine-rich loop which plays a key role in the ATP 
binding. The C-terminal lobe mainly consists on 
hydrophobic α-helical bundles and contains the ele-
ments required for phosphate transfer and for peptide 
substrate binding, including the activation loop. In-
terestingly, the ATP binding pocket is an hydrophobic 
cleft found abutting the hinge region. Both Mnk1/2 
present a 80% identity of the active site despite the N-
terminal lobe of Mnk1 is inclined 10° leaving a slightly 
more closed binding site8. However, Mnks present 
two unique features in contrast to tyrosine kinases4, 11  
consisting of (1) an specific insert in the catalytic do-
main (EAFSE in Mnk2) that seems to promote their 
activation or to guide the substrate recognition and 
(2) the replacement of the conserved DFG-motif for a 
particular DFD-motif (Figure 2).
Figure 2. General structure of the Mnk2 catalytic domain. 
The dotted line indicates that the activation loop has not 
been experimentally solved yet.
staurosporine cercosporamideCGP57380
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DFD-motif is abutting the activation loop, which 
controls the binding of the ligand due to steric hin-
drance. In absence of ligands, Mnk2 adopts an inac-
tive conformation (referred as the DFD-out confor-
mation), sticking Phe227 into the ATP binding pocket 
and blocking the access to the binding site. When 
activated, the Phe227 leaves the hydrophobic pocket 
and flips clockwise about 180°. During this process, 
the salt bridge between Asp226 and Lys234 found on 
the DFD-out conformation is broken and a new salt 
bridge between Asp226 and Lys113 is formed (DFD-in 
conformation) 10.
To the best of our knowledge, the crystal structure 
of the wildtype (wt) Mnk2 protein presenting the 
DFD-in active conformation has not been described 
yet, and it is only available for the DFD-out conforma-
tion (PDB ID: 2AC39). Most of the studies reported in 
literature are leaned on crystallographic structures of 
D228G Mnk2 mutants12-15 (PDB ID: 2HW79, 2AC58), 
considering that this mutation affects the conforma-
tion of Mnk2, but not the ATP binding and its kinase 
activity8. Noteworthy, none of the crystallographic 
models mentioned include information about the ac-
tivation loop, thus it is usually neglected. This would 
lead to an over-simplistic model, particularly when 
molecular dynamics simulations suggested that DFD 
flip is directly associated with conformational chang-
es in the activation loop10, 16. 
In this study we have applied molecular modeling 
techniques to generate an structural model of Mnk2 
DFD-in conformation including the activation loop. 
Having available the three dimensional structure 
of Mnk2 protein allows the design of new inhibitors 
through the application of Structure-Based Drug De-
sign (SBDD) methodologies. Moreover, the effect of the 
activation loop has been evaluated by predicting the in-
teraction mechanism of well-known Mnk2 inhibitors 
(i.e. staurosporine, cercosporamide and CGP57380, 
see Figure 1) by means of molecular docking. 
Computational details
Modelling the activation loop of the Mnk2 DFD-in 
conformation
Structure of the Mnk2 D228G mutant in the ac-
tive conformation (PDB ID: 2HW7) was downloaded 
from the PDB and prepared by using Molecular Oper-
ating Environment (MOE2014.0917). Hydrogen atoms 
were added, minimized and protonation states were 
assigned, and crystallographic waters were removed.
This structure was used as reference to generate two 
additional structural models: (1) a model without the 
activation loop, obtained by manually removing the 
residues of the DFD-motif (D226-G228) included in 
2HW7 and (2) a second model of the wildtype Mnk2 
protein including the activation loop in the active 
conformation. To generate the latest model, residue 
G228 was de-mutated to recover the wildtype se-
quence. The tertiary structure of the activation loop 
(involving L229-C251 residues) was predicted de 
novo by applying the loop modeler module available 
in MOE. All calculations were conducted using the 
Amber12 forcefield. The best loop candidate was se-
lected and energy minimized by molecular dynamics 
(MD) simulations, using AMBER software18, to obtain 
the final model. Amber ff13 forcefield was used for the 
parameters of standard amino acids. The system was 
subjected to a first minimization including a 5000-step 
minimization of TIP3P water molecules followed by a 
20000-step energy minimization of the entire system. 
The system was therefore heated to 300 K in 200 ps us-
ing the Langevin thermostat restraining the backbone 
atoms except the loop atoms using an 8 kcal·mol-1·Å-2 
force constant. Pressure equilibration (1 atm) was 
performed for 1000 ps maintaining the restraints pre-
viously described. The SHAKE algorithm19 was used 
throughout to restrain the bonds involving hydrogens 
and the Particle Mesh Ewald20 method for long range 
electrostatic, while the short range interactions had 
a 10  Å cutoff radius. The production phase was ex-
tended to 20 ns defining a 2 fs time-step. 
Molecular docking
Molecular docking was performed using AutoDock 4 
and AutoDock Tools21on a 1.80 GHz Intel® Core™ i5-
3337U processor with 4 GB RAM. A 126x126x126 Å 
grid was defined to perform a blind docking. Genetic 
Algorithms (GA) were used as docking search method, 
fixing the number of GA runs to 200, defining a popu-
lation size of 500 and a maximum number of 2500000 
evaluations. Evaluation of the results is performed by 
cluster analysis. Alternatively, MOE 2014.09 software 
was applied to include a flexible receptor into docking 
procedure (i.e. induced fit protocol). Docking poses are 
generated using the triangle matcher placement meth-
od (2000 poses) and scored using London ΔG scoring 
function and GBVI/WSA ΔG for rescoring (100 poses).
RESULTS AND DISCUSSION
Three models were considered for the evaluation of 
the activation loop effect: (1) the reported 2HW7 PDB 
structure, which contains the resolved structure for 
only few atoms of the activation loop and presents the 
DFG mutation, (2) the wildtype Mnk2 protein with 
the modelled loop and (3) 2HW7 without loop. 
Two docking methods (rigid receptor and induced 
fit) were compared in order to discuss the relevance 
of the D228G mutation and the presence of the ac-
tivation loop when studying the binding mechanism 
of drug candidates to Mnk2. For this purpose, we 
docked the reference compounds (i.e.  staurosporine, 
cercosporamide and CGP57380, see figure 1) on the 
three Mnk2 models.
Molecular docking protocol was validated (RMSD 
< 0.25  Å) by predicting the binding mechanism of 
staurosporine and comparing the result to the crystal 
structure of staurosporine complexed to the Mnk2 
D228G mutant structure available in the PDB (2HW7). 
Rigid docking
According to the results, the recognition of the ac-
tive site by the ligands could be conditioned by the 
presence of the activation loop when applying rigid 
docking and the protein structure was fixed. 
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Cluster analysis showed that staurosporine was able 
to mostly recognize the active site in all models, sug-
gesting that the presence of the loop did not induce a 
remarkable effect on the location of the ligand. On the 
contrary, the presence of the activation loop hindered 
the access to the active site for cercosporamide and 
CGP57380. The combined effect of activation loop 
and the DFD motif conformations blocked the ac-
tive site abutting the C-helix, moving their preferred 
binding site from the ATP binding site to the helix 
region at the C-terminal lobe (Figure 3).
From Figure 3 it can be seen that an appreciable per-
centage of conformations are located in the ATP bind-
ing site, regardless of the presence of the activation 
loop. Residues included in the active site were defined 
by proximity (4.5 Å) to the crystallized staurosporine-
Mnk2 complex available in literature. Nevertheless, 
conformations located into the active site do not cor-
respond to the best ranked conformations in terms of 
the scoring function and this could lead to confusing 
results. 
Although staurosporine preferentially bounds to 
the ATP binding site, the spatial orientation of the 
most stable binding conformations predicted with 
and without the activation loop were slightly different 
(Figure 4). Structural differences could be appreciated 
when comparing the binding mechanism, obtaining 
two flipped conformations according to a symmetry 
axis, with comparable score. 
 
A) B)
Figure 4. Comparison between the most stable staurospo-
rine conformations predicted by docking when considering 
the Mnk2 protein without activation loop (white) and 
containing a de novo modelled activation loop (black). (A) 
Position of the best ranked staurosporine conformations 
within the Mnk2 protein, corresponding to the active site. 
(B) Comparison between the spatial orientations of both 
conformations obtained. 
According to these results, the activation loop 
may have a pivotal role in drug recognition. More-
over, rigid docking did not allowed to obtain a cor-
relation between the active site recognition and 
the scoring function value. This situation gives 
rise to unrealistic docking results and we hypoth-
esized the need of including protein f lexibility in 
the study.
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Figure 3. Cluster analysis from rigid docking. Molecules are divided in two groups depending on where they bind: the active 
site (black) or other parts of the protein, usually the α-helixes (grey).
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Induced fit docking
Induced fit docking revealed that the flexibility of 
the activation loop may contribute to guide ligands 
towards the active site. Interestingly, reference com-
pounds showed a similar behavior in all models 
when allowing receptor flexibility. Ligands tend to 
bind to the external part of the β-sheets in absence 
of the activation loop. When a small part of the loop 
is present (corresponding to the structure directly 
obtained from the PDB), more conformations are 
found in the helixes despite some conformations 
bind into the active site.
In the presence of the modelled loop a higher per-
centage of conformations end up in the ATP bind-
ing site. The modelled loop guides molecules to the 
Glycine rich loop and avoids binding to the C-helix. 
Interestingly, the conformations with the best score 
are those located in the ATP binding site and con-
formations with a lower score bind to helixes. The 
distribution of docking conformations obtained for 
each model is included in Figure 5. 
Cluster analysis revealed that the model including 
the activation loop de novo modeled is the one that 
allows to lead the higher number of conformations 
with higher score within the active site (Table 1). The 
flexibility of the activation loop is determinant in or-
der to obtain these results. 
Table 1. Percentage of molecules bound to the Mnk2 ATP 
binding site.
1 
 
Table 1. Percentage of molecules bound to the Mnk2 ATP binding site.
Staurosporine CGP57380 Cercosporamide
PDB 28% 20% 12%
Without 
activation loop 18% 15% 11%
De novo
activation loop 33% 36% 22%
In order to make the visualization of these results 
easier, the three dimensional coordinates of each 
Mnk2 residue were projected into the H2 hyperbolic 
plane. This procedure allows the representation of 
multidimensional points into a bidimensional space in 
which the distance between projected points increase 
exponentially with the radii by changing the metric 
definition (in this case, using Poincaré’s disk model) 22. 
Residues were colored according to the protein region 
and their positions were compared with the location of 
staurosporine conformations (Figure 6). 
As expected, results showed that a higher number of 
staurosporine conformations are located close to the 
DFD motive and the ATP binding site. It is a worth 
of attention the effect of the activation loop on the 
Mnk2 projection, which modifies the conformation 
of the protein and induces a change into staurospo-
rine distribution reducing binding affinity towards 
the β-sheets and the C-helix and concentrating con-
formations on the active site.
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Figure 5. Graphical representation of the conformations obtained by induced fit docking.
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Figure 6. Hyperbolic projection of Mnk2 residues resulting 
from flexible docking on PDB (2HW7) and the structure 
with the modelled loop.
These results are in disagreement with methodolo-
gies commonly reported in literature for designing 
new Mnk2 inhibitors. Most of research articles di-
rectly apply molecular docking on the mutated Mnk2 
structure available in the PDB. Our findings suggest 
that these models may be over simplistic and they 
could lead to unrealistic results. The presence of the 
activation loop and considering the flexibility of the 
receptor may be crucial for the correct description of 
the Mnk2-ligand complex and both should be con-
sidered when applying structure-based drug design 
techniques.
CONCLUSIONS
The effect of the activation loop on predicting the 
preferred binding site of Mnk2 inhibitors has been 
evaluated by molecular docking. The wildtype Mnk2 
structure in the DFD-in conformation has been mod-
eled by modifying the structure of Mnk2 D228G 
mutant available in the PDB. The three dimensional 
structure of the activation loop has been predicted 
computationally by de novo design methodologies.
The presence of the activation loop was essential to 
lead ligands towards the active site and receptor flex-
ibility was required in order to obtain reliable results. 
Thus, obtained results suggest that the presence of 
the activation loop is determinant for the correct pre-
diction of the active site of known ligands in docking 
procedures and it should be therefore considered in 
molecular design of new Mnk2 inhibitors.
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